Molecular Profiling

GENETIC5 trials

Sponsors

National Cancer Institute (NCI), Samsung Medical Center, University Health Network, Toronto, Prinses Máxima Center voor kinderoncologie

Conditions

Carcinoma, Non-Small-Cell LungCarcinoma, Pancreatic DuctalCarcinoma, Small Cell LungCarcinoma, ThymicEsophagogastric AdenocarcinomaStomach Neoplasmsrelapse refractory, pediatric oncology, molecular profiling, actionable lesions recidief refractair, kinderoncologie, moleculaire profilering, behandelbare laesies Pediatric Relapsed/Refractory Malignancies

Phase 2

Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies

CompletedNCT01306045

National Cancer Institute (NCI)Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell Lung, Carcinoma, Thymic

Start: 2011-02-08End: 2024-07-17Updated: 2024-10-01

Unknown Phase

The Screening Protocol for The VIKTORY Trial

CompletedNCT02299648

Samsung Medical CenterStomach Neoplasms

Start: 2014-07-25End: 2022-05-17Updated: 2022-06-15

Study of Changes and Characteristics of Genes in Patients With Pancreatic Cancer for Better Treatment Selection

CompletedNCT02750657

University Health Network, TorontoCarcinoma, Pancreatic Ductal

Start: 2015-12-31End: 2025-08-31Updated: 2025-11-18

DCOG-iTHER: towards Individualized Therapies for Children with Relapsed/Refractory Malignancies using Molecular Profiling

Active, not recruitingNL-OMON29251

Prinses Máxima Center voor kinderoncologierelapse refractory, pediatric oncology, molecular profiling, actionable lesions recidief refractair, kinderoncologie, moleculaire profilering, behandelbare laesies Pediatric Relapsed/Refractory Malignancies

Start: 2017-04-18Target: 150Updated: 2024-06-11

Molecular Characteristics of Gastroesophageal Adenocarcinoma (MOCHA): A Prospective Feasibility Study

RecruitingNCT04219137

University Health Network, TorontoEsophagogastric Adenocarcinoma

Start: 2019-11-14End: 2027-11-30Target: 120Updated: 2025-05-14

Related Papers

Abstract B086: External validation of a multimodal machine learning system to predict outcomes in advanced pancreatic cancer in the PASS-01 trial

Cancer Research2025-09-28

Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial.

2025-07-012 citations

Integrative analysis of tumor microenvironment in advanced pancreatic cancer: Unraveling genomic and immune landscape for targeted therapies.

Journal of Clinical Oncology2025-05-28

Multimodal machine learning predictions of treatment response and survival in advanced pancreatic cancer from the COMPASS trial.

Journal of Clinical Oncology2025-05-28

Familial lung cancer: A thirteen-year prospective analysis of participants with germline EGFR T790M pathologic variant.

Journal of Clinical Oncology2025-05-28

Beyond Khorana score 2: Molecular correlates of venous thromboembolism in pancreatic cancer.

Journal of Clinical Oncology2025-01-27

GATA6 expression in advanced pancreatic ductal adenocarcinoma (PDAC) as a prognostic and predictive biomarker in the Canadian COMPASS trial and the Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS.

Journal of Clinical Oncology2024-06-011 citations

Characterizing the genomic landscape of locally advanced pancreatic cancer.

Journal of Clinical Oncology2024-01-20

347. LASER CAPTURE MICRODISSECTION AND WHOLE GENOME SEQUENCING OF ESOPHAGEAL ADENOCARCINOMA SAMPLES WITH MINIMAL TUMOUR

Diseases of the Esophagus2023-08-30

hENT1 as a Predictive Biomarker in PDAC—Response

Clinical Cancer Research2023-08-013 citations

Abstract 173: Genomic characterization of patient-derived pancreatic cancer organoids

Cancer Research2023-04-04

Systemic inflammatory prognostic scores in advanced pancreatic adenocarcinoma.

2023-03-1616 citations

Molecular characterization of long-term and short-term survivors of advanced pancreatic ductal adenocarcinoma.

Journal of Clinical Oncology2022-06-014 citations

Comparison of systematic inflammatory prognostic scores in patients with advanced pancreatic adenocarcinoma.

Journal of Clinical Oncology2022-06-011 citations

GATA6 Expression as a predictor of response to perioperative chemotherapy in resectable pancreatic adenocarcinoma: A multicenter Canadian phase II study (NeoPancONE).

Journal of Clinical Oncology2022-01-1912 citations

Integrative analysis of <i>KRAS</i>-wildtype pancreatic ductal adenocarcinoma reveals unique similarities to extrahepatic cholangiocarcinoma.

Journal of Clinical Oncology2022-01-19

Impact of KRAS mutational status on outcomes in patients with pancreatic cancer (PDAC).

Journal of Clinical Oncology2021-05-202 citations

Familial pancreatic cancer (FPC) status as a clinical biomarker in patients receiving platinum-based systemic therapy: A case-control analysis.

Journal of Clinical Oncology2021-01-201 citations

Chemotherapy, host response and molecular dynamics in periampullary cancer: the CHAMP study.

2020-04-1512 citations

Homologous recombination deficiency (HRD) scoring in pancreatic ductal adenocarcinoma (PDAC) and response to chemotherapy.

Journal of Clinical Oncology2020-02-014 citations

5 more papers not shown